NDA 214096 · Emd Serono INC
Tepmetko
Tepotinib Hydrochloride · Oral
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 3, 2021: To treat non-small cell lung cancer
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Feb 3, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
29
1 Phase 3, 6 recruiting
FAERS reports
691
489 serious, 163 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 17, 2025.
TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. ( 1 )
Mechanism: Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations. Tepotinib inhibits hepatocyte growth factor (HGF)-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways. Tepotinib also inhibited melatonin 2 and imidazoline 1 receptors at clinically achievable concentrations. In vitro, tepotinib inhibited tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells. In mice implanted with tumor cell lines with oncogenic activation of MET, including MET ex14 skipping...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 15, 2024 Supplement 3 · Efficacy OrphanLabelLetterReview
- Feb 3, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- TEPMETKO · TEPOTINIB HYDROCHLORIDE EQ 225MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tepotinib" as an intervention, any sponsor and status, largest first.
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT02864992 · 337 participants · Start Sep 13, 2016 · Primary completion May 16, 2022
Drug: Tepotinib · For: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV
Sites: Duarte, California; Encinitas, California; Orange, California · 176 sites in all
Helsinki University Central HospitalAcademic, hospital or other
NCT05159245 · 250 participants (planned) · Start Dec 10, 2021 · Primary completion Nov 25, 2031
Drug: Alectinib; Cobimetinib and 13 more · For: Advanced Cancer; Solid Tumor; Haematological Malignancy
Sites: Turku, Finland; Helsinki, Finland; Kuopio, Finland · 5 sites in all
EMD SeronoIndustry
NCT01014936 · 149 participants · Start Nov 30, 2009 · Primary completion Oct 31, 2015
Drug: MSC2156119J · For: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Sites: Houston, Texas
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)Completed
EMD Serono Research & Development Institute, Inc.Industry
NCT03940703 · 140 participants · Start Sep 19, 2019 · Primary completion May 11, 2023
Drug: Tepotinib; Osimertinib · For: Non-small Cell Lung Cancer
Sites: Yuma, Arizona; Fountain Valley, California; Long Beach, California · 179 sites in all
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedPivotal-lookingRecruiting
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
NCT06908993 · 133 participants (planned) · Start Dec 9, 2025 · Primary completion Mar 15, 2028
Drug: Tepotinib; Pemetrexed (Alimta) and 7 more · For: Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation
Sites: Besançon, France; Bordeaux, France; Brest, France · 29 sites in all
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaPivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT01988493 · 117 participants · Start Jan 6, 2014 · Primary completion Feb 5, 2018
Drug: Tepotinib 300 mg; Tepotinib 500 mg and 3 more · For: Carcinoma, Hepatocellular
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death114
- oedema66
- diarrhoea58
- oedema peripheral58
- fatigue56
- renal impairment56
- off label use55
- nausea44
- disease progression43
- peripheral swelling39
- decreased appetite27
- blood creatinine increased24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 69 |
| 2022 | 81 |
| 2023 | 183 |
| 2024 | 92 |
| 2025 | 105 |
| 2026 | 157 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tepmetko (Tepotinib HCl)
2024 spending
$40.6M
Beneficiaries
399
1,914 claims
Per beneficiary
$101,670
$404.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $5,416,101 |
| 2022 | $12,150,180 |
| 2023 | $22,472,804 |
| 2024 | $40,566,269 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Multicenter Study
- Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J, Paik PK, Garassino MC, et al. · JAMA Oncol 2023 · Clinical Trial, Phase II, Multicenter Study
- MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J, Vioix H, Pfeiffer BM, et al. · Clin Lung Cancer 2023 · Research Support, Non-U.S. Gov't, Systematic Review
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, et al. · Lancet Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
Raghav A, Jeong GB · Int J Mol Sci 2024 · Systematic Review
- MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Dong Y, Xu J, Sun B, et al. · Mol Diagn Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Emd Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.